Poxel (FRA:7PO) Other Current Liabilities: €17.05 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7PO Poxel SA FRA:7PO
44 GF Score
Price €0.20
GF Value €1.29
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Poxel Other Current Liabilities?

Poxel FRA:7PO -2.00% 44 Other Current Liabilities is €17.05 Mil as of Jun. 2025. GuruFocus rates FRA:7PO with a GF Score™ of 44/100 and a GF Value™ of €1.29 (Possible Value Trap). The stock has 6 warning signs investors should review.

Poxel's other current liabilities for the quarter that ended in Jun. 2025 was €17.05 Mil.

Poxel's quarterly other current liabilities increased from Jun. 2024 (€9.70 Mil) to Dec. 2024 (€12.67 Mil) and increased from Dec. 2024 (€12.67 Mil) to Jun. 2025 (€17.05 Mil).

Poxel's annual other current liabilities increased from Dec. 2022 (€9.94 Mil) to Dec. 2023 (€11.85 Mil) and increased from Dec. 2023 (€11.85 Mil) to Dec. 2024 (€12.67 Mil).

Poxel Other Current Liabilities Related Terms

Poxel Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Poxel's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poxel Other Current Liabilities Chart

Poxel Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.82 7.11 9.94 11.85 12.67

Poxel Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.51 11.85 9.70 12.67 17.05
FRA:7PO
44GF Score
Poxel SA FRA:7PO
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Poxel Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €17.05 Mil mean?
Poxel (FRA:7PO) has a Other Current Liabilities of €17.05 Mil as of Jun. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Poxel.
Is Poxel's Other Current Liabilities too high?
Poxel's current Other Current Liabilities is €17.05 Mil. Overall, Poxel has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Poxel's Other Current Liabilities compare to VRTX and REGN?
Poxel's Other Current Liabilities of €17.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Poxel. Poxel's current Other Current Liabilities is €17.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poxel stock overvalued right now?
Based on GuruFocus' analysis, Poxel (FRA:7PO) is currently considered Possible Value Trap. The stock's GF Value™ is €1.29, compared to a current price of €0.20 — trading 84.8% below its estimated fair value. The current Other Current Liabilities is €17.05 Mil. Poxel's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Poxel (FRA:7PO), the current Other Current Liabilities is €17.05 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Poxel (FRA:7PO) Overvalued in 2026?

Based on GuruFocus' analysis, Poxel stock appears to be undervalued. The current stock price of €0.20 is trading 84.8% below its estimated GF Value™ of €1.29. GuruFocus considers Poxel to be Possible Value Trap.

Key valuation signals for FRA:7PO:

  • Other Current Liabilities: €17.05 Mil
  • GF Value™: €1.29 vs. price of €0.20 (84.8% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the FRA:7PO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Poxel Business Description

Other Exchanges 0RA2:UKPOXEL:France
Address 259/261 Avenue Jean Jaures, Immeuble le Sunway, Lyon, FRA, 69007
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
44GF Score

Get the complete analysis for FRA:7PO

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€1.29
GF Value